Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Advances in™ the Management of Chronic Myeloid Leukemia

Release Date: January 31, 2019
Expiration Date: January 31, 2020
Media: Internet - based

Activity Overview

While the advent of tyrosine kinase inhibitor therapy for the treatment of patients with CML has significantly improved survival outcomes, clinicians who care for these patients still face several management challenges throughout the disease continuum. Familiarity with recent guidelines and evidence-based strategies to monitor patient treatment response is essential to optimize patient outcomes, as is awareness of the latest data on management approaches for patients who experience treatment-associated adverse events or are refractory to initial lines of therapy. In addition, because your patients with CML may be on TKI therapy for many years, it is crucial for you to be cognizant of long-term safety considerations for these medications, as well as other conditions that may necessitate treatment modification.

To help you meet these challenges, this activity has been developed to provide you with the latest information on therapeutic advancements for patients with CML. Audio clips provide expert faculty commentary on a variety of topics, including the influence of recent studies on the treatment paradigm for patients with newly-diagnosed CML, assessment of treatment response, making informed decisions to respond to first line therapy outcomes, and evaluation of patient- and disease-specific factors that may influence the decision to modify TKI therapy.

Benefits of Completing Activity

  • Increase your familiarity with evidence-based guidelines and recent clinical data that may help to optimize outcomes for your patients with CML
  • Obtain expert faculty perspectives on commonly encountered clinical scenarios for patients with CML

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, pathologists, and nurses who treat patients with chronic myeloid leukemia (CML). Nurse practitioners, physician assistants, pharmacists, and other healthcare professionals interested in the treatment of CML are also invited to participate.

Educational Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Apply expert guidelines for monitoring responses (method and timing) and evaluating whether key time-based response milestones have been achieved
  • Discuss implications of response to therapy on subsequent treatment decision-making among patients with chronic myeloid leukemia (CML)
  • Describe the long-term safety implications of treatment with BCR-ABL tyrosine kinase inhibitors and how treatment decisions are impacted by patient-specific characteristics
  • Differentiate among treatment options for CML and discuss the implications of response to therapy on subsequent treatment decision-making

Faculty, Staff, and Planners' Disclosures


Michael J. Mauro, MD
Michael J. Mauro, MD
Leader, Myeloproliferative Neoplasms (MPN) Program
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York, NY

Disclosures: Consultant: Novartis, Bristol-Myers Squibb, Takeda, Pfizer

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By